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The management of vestibular schwannoma (VS) with residual tumor following incomplete 
resection remains controversial and little is known regarding postoperative tumor volume changes. 
The behavior of residual tumors was analyzed for 111 patients who underwent surgery for newly 
diagnosed VS between September 2006 and July 2017. The postoperative tumor volume changes 
were assessed during a mean follow‑up of 69 months (range 36–147 months). Fifty‑three patients 
underwent imaging surveillance following incomplete resection. There was no residual tumor growth 
in 44 patients (83%). A significant regression of residual tumor volume was noted in the no growth 
group at postoperative 1 year (p = 0.028), 2 years (p = 0.012), but not from 3 years onwards. Significant 
predictors of regrowth were immediate postoperative tumor volume ≥ 0.7  cm3 (HR 10.5, p = 0.020) 
and residual tumor location other than the internal auditory canal (IAC) (HR 6.2, p = 0.026). The mean 
time to regrowth was 33 months (range 5–127 months). The 2‑, 5‑, and 10‑year regrowth‑free survival 
rates were 90.6%, 86.8%, and 83%, respectively. In conclusion, significant residual tumor regression 
could occur within 2 years for a VS with an immediate postoperative tumor volume less than 0.7  cm3 or 
residual tumor in IAC.
The goal of vestibular schwannoma (VS) treatment is to achieve long-term tumor control and preserve neurologi-
cal function. Treatment modalities include conservative management, microsurgery, radiosurgery or combination 
of both micro- and radiosurgery. Surgical resection remains the primary treatment that can provide the greatest 
chance of a long-term cure, especially for large, symptomatic  tumors1. However, the narrow surgical corridor 
of the cerebellopontine angle and the intimate relationship of VS with delicate neurovascular structures such 
as the facial nerve have resulted in 30–50% rates of facial nerve dysfunction with complete  resection2–5. Recent 
studies have shown that a planned incomplete resection followed by upfront gamma knife radiosurgery (GKRS) 
could achieve both satisfactory tumor control and neurological  outcome6–9. Unfortunately, incomplete resection 
carries the risks of tumor regrowth and higher radiation-dose to reduce the risks of regrowth that could lead to 
tumor swelling, cerebral edema, and cranial nerve  neuropathy9–13. The inherent, additional surgical risks must 
also be taken into account should GKRS fail to control the  tumor14. The question of when and under what cir-
cumstances should GKRS be performed following incomplete resection will depend on the incidence and the 
rate of tumor regrowth, and the benefit on neurological outcome. Several studies in the past have focused on 
the long-term natural history of VS, but little is known about the long-term behavior of residual VS following 
incomplete surgical resection. In this study, we report a long-term analysis of patients who underwent surgery 
for newly diagnosed VS. We analyze the behavior of residual tumors after incomplete resection by measuring the 
sequential postoperative tumor volume changes. We also assess the neurological outcome, especially the facial 
nerve function. The purpose of the study is not to support one management approach over another, but to better 
understand the behavior of residual VS following incomplete resection.
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Methods
A long-term, retrospective, and consecutive analysis was performed on 111 patients who underwent surgical 
resection for newly diagnosed VS from September 2006 to July 2017. The data of 53 patients who had residual 
tumor following incomplete surgical resection were put on imaging surveillance for the residual tumor. Patients 
with radiologic and clinical follow-up of 3 years or longer matched the inclusion criteria of this study. There 
were no lost to follow-up among patients who had residual tumor following incomplete resection. The deci-
sion to observe rather than to undergo an upfront GKRS was made depending on the residual tumor volume, 
functional outcome, and patient’s preference after informed consent. The data was gathered and analyzed after 
obtaining informed consent from every patient. The study was approved by the Institutional Review Board of 
Gangnam Severance Hospital Human Research Protection Center and conducted in accordance with the ethical 
guidelines of the Declaration of Helsinki.
Data interpretation. All patients underwent magnetic resonance imaging (MRI) including T2-weighted 
and gadolinium enhanced T1-weighted axial, coronal, and sagittal images, acquired at 1 mm slice thickness. A 
scheduled imaging surveillance protocol with gadolinium enhanced MRI was performed for 15 years from the 
day of the surgery. The imaging studies were obtained before surgery, 3 months after surgery (immediate), annu-
ally for the first 3 years, and every 2 to 3 years thereafter. Pre- and postoperative tumor volumes were assessed 
by two neurosurgeons using Leksell GammaPlan software version 8.0 (Elekta AB). All performed images were 
also interpreted by two neuroradiologists who were blinded to patient information. Gross-total resection (GTR) 
was defined as complete tumor removal confirmed by the surgeon intraoperatively with no evidence of residual 
tumor on immediate and 1  year postoperative MRIs. Near-total resection (NTR) was defined as above 95% 
tumor resection with a thin layer of residual tumor on a neurovascular structure, confirmed by the surgeon 
intraoperatively, and on immediate and 1 year postoperative MRIs. Subtotal resection (STR) and partial resec-
tion (PR) were defined as 90–95% and less than 90% tumor resection, confirmed by the surgeon intraoperatively, 
and on immediate and 1 year postoperative MRIs, respectively. Tumor regrowth was defined as residual, enhanc-
ing, solid tumor volume increase of more than 20% compared to the first postoperative MRI with persistent 
growth on consecutive  scans15. Neurological outcome was assessed using House–Brackmann (HB) classification 
for facial and Gardner–Robertson Hearing Scale (GR) for cochlear nerve function.
Surgical procedure. The choice of surgical approach depended on the size, location, surgical line-of-sight, 
extent of the tumor, and surgeon’s preference. The facial nerve was routinely monitored and localized using facial 
nerve electromyography and stimulator throughout the surgical procedure. The cochlear nerve was monitored 
using intraoperative brainstem auditory evoke potentials if the patient had serviceable hearing. The cisterna 
magna was opened to relieve intracranial pressure and minimize cerebellar retraction. The roof of the internal 
auditory canal (IAC) was drilled to remove the tumor and decompress the canal to avoid retraction injury to 
the nerves before intracapsular debulking was performed with an ultrasonic aspirator. The facial nerve was first 
identified at the meatal segment, and then at the root entry zone to perform both antero- and retrograde dis-
section of the nerve. The intention of the surgery was a GTR, but an incomplete resection was performed if the 
tumor capsule was adherent to the facial nerve.
Statistical analysis. Tumor characteristics, size, and volume changes were analyzed and compared between 
the no growth and regrowth group using Mann–Whitney U test. A Fischer’s exact test was used to compare 
categorical variables. Univariate logistic regression analysis was conducted to determine significant predictors 
of regrowth. A Cox proportional hazards model was used to report hazard ratios of significant factors with 
95% confidence intervals. A stepwise multivariate logistic regression analysis was also performed to seek any 
independent predictors of regrowth. Regrowth-free survival was calculated using the Kaplan–Meier method. 
Data analyses were performed using SPSS software (version 18.0, SAS Institute Inc., Chicago, IL, USA). Graphs 
depicting long-term tumor volume changes and facial nerve outcome at last follow-up were plotted using Micro-
soft Excel software (version 16.0, Microsoft Inc., Redmond, WA, USA). Two-tailed and p values of ≤ 0.05 were 
considered statistically significant.
Results
Patient and tumor characteristics. One hundred and eleven patients underwent surgery for newly diag-
nosed VS, in which 51 (45.9%) achieved GTR with no recurrence during the study period (Fig. 1). Among 60 
patients (54.1%) with residual tumor following surgical resection, 7 patients underwent upfront GKRS and 53 
patients were put on imaging surveillance for the residual tumors. Of the 53 patients with incomplete resections, 
there were 36 female (67.9%) and 17 male (32.1%) patients with a mean age of 50 years (range 20–75 years) 
(Table 1). The mean tumor length, width, height, and volume were 3.4 cm (range 1.2–6.1 cm), 2.6 cm (range 
0.8–4.5 cm), 2.6 cm (range 1.0–4.8 cm), and 13.5  cm3 (range 0.7–42.7  cm3), respectively. All patients had tumors 
that were Koos grade III (28.3%) or IV (71.7%) with a solid (64.2%) or cystic (35.8%) character. The foremost 
symptom was hearing difficulty (75.5%) with a GR class of I to V in 24.5%, 20.8%, 28.3%, 5.7%, and 20.8% of 
patients, respectively. The rate of preoperative unserviceable hearing (GR classes III to V) was 54.8%. The pre-
operative facial nerve function was mostly normal (94.3%) with a HB grade I. There was 1 patient (1.9%) with 
HB grade II and 2 (3.8%) with HB grade IV facial nerve function. The mean radiologic and clinical follow-up 
was 69 months (range 36–147 months). The rate of 3-, 5-, 7-, and 10-year radiologic and clinical follow-up were 
100%, 52.8%, 26.4%, and 9.4%, respectively.
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Tumor control and radiologic outcome. Retrosigmoid lateral suboccipital (92.5%) and presigmoid ret-
rolabyrinthine posterior transpetrosal (7.5%) approaches were performed for 53 patients with incomplete resec-
tions. NTR was achieved in 39 patients (73.6%), STR in 5 patients (9.4%), and PR in 9 patients (17%). The mean 
extent of resection (EOR) for incomplete resections was 95.8% (range 77.8–99.8%) with a mean immediate post-
operative tumor volume of 0.36  cm3 (range 0.01–3.64  cm3). The most common site of residual tumor was IAC 
(83%), followed by the brain stem (5.7%), trigeminal nerve (5.7%), brain stem and facial nerve (3.8%), and facial 
nerve (1.9%) (Fig. 2). There was no residual tumor growth in 44 patients (83%) and regrowth in 9 patients (17%) 
during the study period. There was significant reduction of tumor volume compared to the prior MRI scan in 
the no growth group at postoperative 1 year (p = 0.028) and 2 years (p = 0.012), but not from 3 years (p = 0.279) 
onwards (Fig. 3). The mean time from surgery to residual tumor growth in the regrowth group was 33 months 
(range 5–127 months), in which 8 patients underwent salvage GKRS and 1 patient underwent surgical resection 
(Fig. 4). The were 2 patients (22.2%) with persistent residual tumor growth after GKRS. The mean regrowth-free 
period for VS with incomplete resections was 131 months (95% CI 114–148 months). The regrowth-free survival 
at 2, 5, and 10 years was 90.6%, 86.8%, and 83%, respectively (Fig. 5A).
Predictors of tumor regrowth. There were no differences in patient and tumor characteristics such as 
age, sex, preoperative tumor size and volume, and Koos grade between the no growth and regrowth group 
(Table 2). The mean EOR of no growth and regrowth group was 96% and 95.2%, respectively (p = 0.903). The 
mean preoperative, immediate postoperative, 1-, 2-, 3-, 5-, 7-, 10-, and 13-year tumor volumes were 12.2  cm3, 
0.27  cm3, 0.19  cm3, 0.14  cm3, 0.14  cm3, 0.12  cm3, 0.08  cm3, and 0.11  cm3 in the no growth and 18.5  cm3, 0.8 
 cm3, 0.69  cm3, 1.04  cm3, 1.21  cm3, 1.41  cm3, 1.95  cm3, and 0.35  cm3 in the regrowth group, respectively. On uni-
variate analysis, significant predictors of regrowth were immediate postoperative tumor volume ≥ 0.7  cm3 (HR 
10.5, 95% CI 1.445–76.289, p = 0.020) (Fig. 5B) and residual tumor location other than IAC (HR 6.2, 95% CI 
1.246–31.250, p = 0.026) (Fig. 5C), but no significance could be established on multivariate analysis.
Functional outcome and surgical complications. The postoperative facial nerve function at last fol-
low-up was HB grades I to V in 50.9%, 26.4%, 17%, 3.8%, and 1.9% of patients, respectively. Compared to the 
facial nerve status before surgery, 50.9% of patients had completely normal facial nerve function, 3.8% had no 
change, 28.3% had deterioration by 1 grade, 13.2% by 2 grades, 1.9% by 3 grades, and another 1.9% by 4 grades. 
The rates of optimal HB (grades 1 and 2) were 71.8% for NTR, 80% for STR, and 100% for PR (Fig. 6). Postop-
eratively, 7.5% of patients retained serviceable hearing, unserviceable hearing remained the same in 54.8%, and 
37.7% had deterioration. There were no differences in postoperative facial nerve function and hearing between 
the no growth and regrowth group. As for surgical morbidities, 5 of 44 patients (11.4%) in the no growth group 
had neurological deterioration. Three patients with facial numbness had near-complete recovery at last follow-
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Table 1.  Summary of patients with incomplete surgical resection for vestibular schwannomas. BS brain stem, 
CN5 trigeminal nerve, FN facial nerve, HB House–Brackmann, IAC internal auditory canal, NTR near-total 
resection, PR partial resection, STR subtotal resection. *Values shown are mean.
Variable Value


















Preoperative tumor volume in  cm3 (range) 13.5 (0.7–42.7)




Extent of resection in % (range) 95.8 (77.8–99.8)
Postoperative tumor volume in cm3
Immediate 0.36 ± 0.54
1-year 0.28 ± 0.37
2-year 0.31 ± 0.51
3-year 0.35 ± 0.55
5-year 0.54 ± 1.11
7-year 1.01 ± 2.08
10-year 0.20 ± 0.22




FN + BS 2 (3.8)
FN 1 (1.9)








Facial numbness 3 (5.7)
Diplopia 2 (3.8)
Regrowth (%) 9 (17)
Surgery to regrowth time in months (range) 33 (5–127)
Follow-up time in months (range) 69 (36–147)
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up and the diplopia of 2 patients could be corrected with prism glasses. There were no surgical morbidities in 
the regrowth group.
Discussion
The management of large VSs has evolved over the last 30 years based on long-term tumor control and preser-
vation of neurological function. Historically, a complete surgical resection carried the least risk of a long-term 
recurrence, but came at a 30–50% risk of facial nerve  dysfunction2–5,16. The concern that an aggressive surgical 
resection would cause inadvertent trauma to the facial nerve and other critical neurovascular structures has 
recently brought a shift in surgical practice. With advances in radiosurgical techniques, a planned incomplete 
resection followed by upfront GKRS has become a feasible treatment strategy that could achieve both satisfac-
tory tumor control and neurological  outcome6–9,17. However, an incomplete resection with upfront GKRS is 
not completely free from risks of its own such as pseudoprogression, cerebral edema, radiation injury to the 
brain stem, cranial nerve neuropathy, malignant transformation, and added surgical risks should GKRS  fail9–14. 
Therefore, it is important to understand the behavior of residual tumors following an incomplete resection. 
Some authors showed that small, devascularized residual tumors do not  grow18–20, while others proved that the 
proliferative activity of the tumor itself contributes to  regrowth21–23. The question of whether the residual tumor 
will grow or not will depend on the pattern of regrowth, in which the incidence and rate of regrowth, and the 
benefit on neurological outcome need to be addressed. So far, the long-term behavior of residual tumors and 
the clinicopathologic factors that contribute to regrowth are not well understood. Therefore, we explored the 
long-term behavior of residual VS following incomplete resection, in terms of sequential tumor volume changes 
and assess the neurological outcome.
Definition of regrowth and extent of resection. The definition of two terminologies, regrowth and 
EOR has to be clarified before assessing the long-term behavior of residual tumors and the factors that affect 
them. There is currently no gold standard to define the growth of residual tumor in literature. Hence, many 
authors have traditionally determined regrowth as tumor size increase in its greatest dimension on follow-up 
MRIs. This could be imprecise if 2-dimensional diametric measurements are used since a true residual tumor 
size is difficult to compare from one examination to another, especially if the tumor is small. In this study, tumor 
regrowth was defined as residual, enhancing, solid tumor volume increase of more than 20% compared to the 
first postoperative MRI scan with persistent growth on consecutive  scans7–9,15. Postoperative leptomeningeal 
and perineural remodeling can be difficult to distinguish from a true residual tumor or regrowth in early post-
operative MRI  scans15,24,25, therefore the first postoperative scan was performed at postoperative 3 months with 
3-dimensional volumetric determination for every scan. The same principles were applied to determine EOR by 
measuring the volume of residual tumor on postoperative 3 month  MRI24,25. The surgeon’s subjective intraopera-
Figure 2.  Preoperative (A,I,O), immediate (B,J,P), 1- (C,K,Q), 2- (D,L,R), 3- (E,M,S), 5- (F,N,T), 7- (G,U), 
and 10-year (H) postoperative gadolinium enhanced T1-weighted axial MR images of patients with residual 
tumor (white arrows) following incomplete resection. (A–H) The residual tumor in IAC of a patient with partial 
resection (85.2% extent of resection) gradually regressed from an immediate postoperative tumor volume of 
1.19  cm3 (B) to 0.01  cm3 (H) over a follow-up of 147 months. The patient had a normal facial nerve function at 
last follow-up. (I–N) The residual tumor in IAC of a patient with subtotal resection (93% extent of resection) 
gradually regressed from an immediate postoperative tumor volume of 0.62  cm3 (J) to 0.2  cm3 (N) over a 
follow-up of 62 months. The patient had a normal facial nerve function at last follow-up. (O–U) The residual 
tumor at the brain stem of a patient with near-total resection (96.2% extent of resection) gradually regressed 
from an immediate postoperative tumor volume of 0.67  cm3 (P) to 0.38  cm3 (U) over a follow-up of 84 months. 
The patient had a facial nerve function of HB grade II at last follow-up.
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tive observation of EOR was also added to our definition considering the fact that not all residual tumors appear 
on early postoperative MRI scans, especially after NTR.
Behavior of residual tumors. The reported incidence of regrowth in large series that observed the behav-
ior of residual VS after incomplete resection ranged from 6 to 21%, which was consistent with 17% of this study 
(Table 3). The reported mean interval between surgery and regrowth was 33–47 months with a range between 
7.2 and 108 months compared to 33 months (range 5–127 months) of the present  series17,26–33. Considering the 
benign, slow-growing nature of VS, a long-term radiologic follow-up is necessary to validate the rate and interval 
of incidence. The present series underwent a scheduled imaging surveillance protocol for a mean 69 months 
(range 36–147 months). No patients were lost to follow-up with a 3-, 5-, 7-, and 10-year radiologic follow-up of 
100%, 52.8%, 26.4%, and 9.4%, respectively. The patients with prior micro- or radiosurgery were excluded from 
the analysis to understand the true behavior of residual VS following incomplete resection. According to the 
long-term observation of the present and other studies, patients with incomplete resections are subjected to an 
imaging surveillance for at least 10 years with a regrowth peak around 3 years after surgery. During the observa-
tion period, residual tumors that did not grow had significant regression of tumor volume compared to the prior 
MRI scan at postoperative 1 year (p = 0.028) and 2 years (p = 0.012), but not from 3 years (p = 0.279) onwards, 
which was consistent with the findings of Akinduro et al.26. It can be postulated that surgical devascularization 
could lead to significant necrosis and shrinkage of the residual tumor for the first 2  years after  surgery18–20. 
Hence, an imaging surveillance period of at least 2 years without further intervention could be suggested con-
sidering the inherent risks of upfront  GKRS9–14.
Predictors of regrowth. Several factors including  EOR16,17,28, residual tumor  volume17,25,27,34–36, and the 
proliferative activity of the tumor  itself21–23 have been reported to contribute to regrowth after incomplete resec-
tion of VS, but still, little is known about the significant clinicopathological  factors24,26,29–33. In this study, an 
immediate postoperative tumor volume ≥ 0.7  cm3 had almost an 11-fold greater risk and residual tumor location 
other than IAC had a sixfold greater risk of a regrowth than tumors that were less than 0.7  cm3 or in IAC. There-
fore, residual tumors with a tumor volume less than 0.7  cm3 or in IAC could be possible candidates for imaging 
surveillance without further intervention. At least with the data in literature so far, residual tumor volumes 
exceeding 2  cm3 are not good candidates for  observation17,25,34–36. There was no significance of EOR on regrowth 
Figure 3.  Graph outlining long-term tumor volume changes of patients with no residual tumor growth 
after incomplete resection. The y axis indicates the percentage of residual tumor volume compared to the 
preoperative tumor volume. There was significant reduction of tumor volume compared to the prior MRI scan 
at postoperative 1 year (p = 0.028) and 2 years (p = 0.012), but not from 3 years (p = 0.279) onwards.
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in the present series. This could be due to the higher mean EOR for incomplete surgical resections (95.8%) and 
lower mean immediate postoperative tumor volume (0.36  cm3) than other reported  series17,26–31,33,34. The exclu-
sion of patients with GTR in our analysis could have also contributed to the insignificance of EOR on regrowth.
Figure 4.  Graph outlining long-term tumor volume changes of patients with residual tumor growth after 
incomplete resection. The y axis indicates the percentage of residual tumor volume compared to the preoperative 
tumor volume. The mean time from surgery to residual tumor growth was 33 months (range 5–127 months). 
There were two patients with a late regrowth at postoperative 76 and 127 months. Among patients with residual 
tumor growth, 8 patients underwent salvage GKRS and 1 patient underwent salvage surgical resection. There 
were 2 patients (22.2%) with persistent residual tumor growth after GKRS and are under consideration for a 
salvage surgical resection.
Figure 5.  Kaplan–Meier curves of regrowth-free period following incomplete resection (A) and dichotomized 
for immediate postoperative tumor volume (B), and site of residual tumor (C).
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Extent of resection and functional outcome. Among patients with incomplete resections for VS, opti-
mal facial nerve outcomes (HB grades I and II) have been reported to be 51–84% for NTR and 55–100% for 
 STR17,26–33. The postoperative facial nerve function of the present study was within the range of the previous 
reports, whereby 71.8%, 80%, and 100% of NTR, STR, and PR had HB grades I and II, respectively. Although 
no statistical difference could be established in facial nerve outcome according to EOR the two factors seemed 
to have an inverse correlation. Nevertheless, the overall rate of no facial weakness at all (HB grade I) was lower 
than expected compared to other  series17,26–33. This could be attributed to the larger preoperative tumor size 
and volume, and higher mean EOR than the reported  series17,26–33. A larger tumor puts the facial nerve under 
tension which increases the likelihood of stretch injury and hypovascularization, resulting in poor facial nerve 
 outcomes37,38. With regards to EOR, an inverse correlation between facial nerve outcome and EOR is not always 
true as long as care is taken to preserve the facial  nerve28,29,31, which can also diminish as EOR increases. Surgical 
techniques such as IAC unroofing before tumor debulking, intracapsular tumor resection, and leaving behind 
any adherent tumor at the porus acousticus can minimize direct and indirect injury to the facial nerve. In the 
same sense, postoperative hearing will be retained as long as the anatomy and vascularity of the cochlear nerve 
is  preserved7–9.
Limitations. There are a small number of patients in each no growth and regrowth group, especially in 
the latter. Considering the benign, slow-growing nature of VS, regrowth is uncommon with 5- and 10-year 
regrowth-free survival rates reaching up to 85%. Consequently, a long term follow-up is essential to validate the 
incidence, rate, and interval of regrowth. The present series underwent a long-term imaging surveillance with 
no patients lost to follow-up. However, a longer follow-up might be needed as two of our patients had a late 
regrowth at postoperative 76 and 127 months. The lack of standard norm for regrowth and EOR is another dif-
ficulty when it comes to validating the results and comparing them with other published reports. In this study, 
Table 2.  Characteristic differences between no growth and regrowth group following incomplete surgical 
resection for vestibular schwannomas. CPA cerebello-pontine angle, HB House-Brackmann, IAC internal 
auditory canal, NA not applicable, NTR near-total resection, PR partial resection, STR subtotal resection. 
*Values shown are mean ± SD.
No growth Regrowth P
Patients 44 9
Age (years)* 50 ± 13.6 49.7 ± 11.2 0.820
Sex, M/F 13/31 4/5 0.445
Tumor size (cm)*
Length 3.3 ± 1.2 4 ± 1 0.064
Width 2.6 ± 0.9 2.9 ± 0.9 0.312
Height 2.5 ± 0.9 3.1 ± 0.8 0.064
Koos grade NA
III 15 (34.1) 0 (0)
IV 29 (65.9) 9 (100)
Tumor character 0.706
Solid 29 (65.9) 5 (55.6)
Cystic 15 (43.1) 4 (44.4)
Preoperative HB grade NA
I–II 42 (95.5) 9 (100)
III–V 2 (4.5) 0 (0)
Preoperative tumor volume  (cm3) 12.2 ± 9.9 18.5 ± 12.3 0.128
Extent of resection 0.684
NTR 33 (75) 6 (66.7)
STR + PR 11 (25) 3 (33.3)
Extent of resection (%)* 96 ± 4.9 95.2 ± 5.2 0.903
Immediate postoperative tumor volume (cm3) 0.030
 < 0.7 42 (95.5) 6 (66.7)
 ≥ 0.7 2 (4.5) 3 (33.3)
Site of residual tumor 0.035
IAC 39 (88.6) 5 (55.6)
CPA 5 (11.4) 4 (44.4)
Postoperative HB grade 0.665
I–II 33 (75) 8 (88.9)
III–V 11 (25) 1 (11.1)
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a scheduled imaging protocol, 3-dimensional volumetric determination, and an immediate postoperative MRI 
taken at 3 months were adopted to overcome the ambiguous definition of regrowth. The same principles were 
applied to the definition of EOR by adding the surgeon’s subjective intraoperative observation of EOR as not all 
residual tumors appear on early postoperative MRI. The lack of data on the proliferative activity of VS is another 
weakness of this study since it has been reported to be a strong predictor of regrowth. The routine examination 
on the proliferative activity of the tumor had begun in the later stages of this study period and could not be 
included in the analysis. Finally, a comparison between observation and upfront GKRS for the residual tumors 
is beyond the scope of this study. The purpose of this study is not to support one management approach over 
another, but to share our findings of the behavior of residual VS after incomplete resection.
Conclusion
Significant residual tumor regression could occur within 2 years for a VS with an incomplete surgical resection. 
Residual tumors with a tumor volume less than 0.7  cm3 or in IAC could be possible candidates for imaging sur-
veillance without further intervention. Regrowth peak around 3 years after surgery and patients with incomplete 
resections are subjected to an imaging surveillance for at least 10 years as late regrowth can occur. The conclusion 
Figure 6.  Graph summarizing facial nerve outcome at last follow-up according to extent of resection for 
vestibular schwannomas with incomplete resection. The rates of optimal HB (grades 1 and 2) were 71.8% for 
NTR, 80% for STR, and 100% for PR.
Table 3.  Literature review of large series investigating the behavior of residual tumors following incomplete 
surgical resection for vestibular schwannomas. FN facial nerve, FU follow-up, GTR gross-total resection, NA 
not applicable/available. *Values shown are mean and the percentages have been rounded up.
Authors (year) Pts (n) Non-GTR (%)
Residual tumor 
volume*  (cm3)
FN grade 1 and 
2 (%) Observation (%)
Regrowths among 
observation (%)
Surgery to regrowth 
time* (mos) FU time* (mos)
Haque et al. (2011) 151 96/151 (64) NA 97 96/96 (100) 20/96 (21) 47 72
Martin et al. (2012) 212 65/212 (31) NA 55 65/65 (100) 5/65 (8) NA 66
Carlson et al. (2012) 203 59/203 (29) NA NA 59/59 (100) 7/59 (12) NA 42
Chen et al. (2014) 111 111/111 (100) NA 49 111/111(100) 7/111 (6) 41 45
Monfared et al. 
(2016) 73 61/73 (84) 1.1 81 61/61 (100) 13/61 (21) 35 38
Syed et al. (2016) 450 42/450 (9) NA 59 42/42 (100) 3/42 (7) NA 73
Troude et al. (2018) 159 143/159 (90) 0.56 84 66/143 (46) 12/66 (18) 37 59
Present study 111 60/111 (54) 0.36 77 53/60 (88) 9/53 (17) 33 69
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that residual tumors could be observed rather than preceded with upfront GKRS should be carefully interpreted, 
taking into account the incidence of tumor regrowth and the benefit on neurological outcome.
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